Please login to the form below

Not currently logged in
Email:
Password:

New EU approval for Roche’s Tarceva

The European Commission has approved Roche's cancer treatment Tarceva for first-line use in patients with a certain type of non-small cell lung cancer

The European Commission (EC) has approved Roche's cancer treatment Tarceva (erlotinib) for first-line use in patients with a certain type of non-small cell lung cancer (NSCLC).

The drug, which is already approved as a secondary treatment in NSCLC and for metastatic pancreatic cancer, is now available for patients with advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) activating mutations.

EGFR is a protein that extends across the cell membrane that can lead to accelerated cell growth and division and development in metastatic tumours. In some cases of NSCLC, the EGFR proteins can undergo mutations increasing their activity.

Roche said that treatment with Tarceva for patients with the condition had been shown to more than triple the number of people whose tumours shrank.

Dr Hal Barron, chief medical officer and head, global product development, Roche, said the approval was important as it provided an earlier chance for patients to begin therapy.

He stated: "These patients may derive greater benefit when the medicine is used as an initial treatment."

1st September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics